Healthcare
Big Boosts In Revenues For The Vaccine Makers
Johnson & Johnson Johnson & Johnson’s revenues rose by 13.6% to $93.8 billion in 2021. The firm projects sales to reach between $98.9 billion to $100.4 billion in 2022. It aims to provide up to 900 million shots of the Janssen Covid19 vaccine throughout 2022 to the COVAX and AVAT vaccination initiatives. However, the firm’s single dose vaccine faced controversy in 2021, fueled by reports of rare blood clots in US patients. Although the Janssen shot was recommended by the Centers for Disease Control as a booster dose in October 2021, the US agency warned of rare side effects, instead recommending rival firms Pfizer-BioNTech or Moderna vaccines.
Pfizer
AstraZeneca
Moderna
Pfizer’s revenues rose to $81.3 billion in 2021, nearly double the $41.7 billion recorded the previous year, with Covid-19 vaccine sales contributing $36.8 billion to total revenues. It delivered 2.2 billion doses of the Pfizer-BioNTech Covid-19 vaccine in 2021 and expects to manufacture up to four billion doses by the end of 2022. In March 2022, Pfizer began a pediatric study of its Covid-19 vaccine pill, Paxlovid, and plans to file for full regulatory approval in the US. The firm forecasts $54 billion in combined revenues from its Covid-19 vaccines and Paxlovid in 2022. It proposed to whollyacquired clinical company Arena Pharmaceuticals for $6.7 billion in December 2021, and aims to close the deal in the first half of 2022.
AstraZeneca’s total revenue surged by 41% to $37.4 billion in 2021, with its Covid-19 products, Vaxzevria and Evusheld, contributing $4.12 billion to total revenue. The Cambridge-based firm supplied 2.5 billion Vaxzevria doses to over 180 countries in 2021. Vaxzevria and Evusheld were in phase three of clinical development as of February 10, 2022. Evusheld is approved for emergency use in the U.S. and launched in the EU, Japan, and China in the first half of 2021. AstraZeneca acquired Alexion Pharmaceuticals in July 2021. The pharma giant paid $13.3 billion and over 236 million new AstraZeneca shares to the U.S.-based firm’s shareholders. It made $3.07 billion in sales in 2021 from the newly-formed “Alexion, AstraZeneca Rare Disease” division.
Moderna made $18.5 billion in total revenues in 2021, 95.7% of which came from its Covid-19 vaccine sales. In 2021, Moderna made $17.7 billion from its Spikevax Covid-19 vaccine sales and supplied 807 million doses to over 60 countries. The firm expects to manufacture up to three billion doses in 2022. Spikevax became the second fully FDAapproved Covid-19 vaccine, after Pfizer-BioNTech’s, on January 31, 2022. Its Omicronspecific booster shot is under study as of February 24, 2022. Moderna now plans to accelerate its mRNA-based operations, including launching vaccine initiatives, product developments, mRNA scientist fellowship programs, and an investment of up to $500 million to establish its first mRNA manufacturing facility in Kenya, Africa.
2021 Revenue
% Increase Year-Over-Year In 2021
$93.8 B
$81.3 B
$37.4 B
$18.5 B
13.6%
95%
41%
2,200%
F O R B E S M I D D L E E A S T.C O M
APRIL 2022
BY KHADIJAH KHOGEER
LEADERBOARD
10
Driven by their Covid-19 vaccine sales, Pfizer, Moderna, AstraZeneca, and Johnson & Johnson made a combined $231 billion in revenues in 2021. These four healthcare heavyweights are also expecting big gains in 2022, capitalizing on booster requirements.
